PACS developers Agfa of Mortsel, Belgium, and Mitra of Waterloo, Ontario, have formed a joint-venture company called Impax Technology to develop and sell PACS software based on Agfa’s Impax product line. The new company will be headed by Mitra chief
PACS developers Agfa of Mortsel, Belgium, and Mitra of Waterloo, Ontario, have formed a joint-venture company called Impax Technology to develop and sell PACS software based on Agfas Impax product line. The new company will be headed by Mitra chief executive Eric Peterson and will also sell Impax software to other companies.
Agfa has become the industrys leading PACS company thanks largely to the Impax software, which Mitra developed for Agfa. The companies have been in discussions for the last several months about restructuring their eight-year relationship. The joint-venture deal allows Agfa to maintain access to the Impax software while creating a new pool of potential OEM customers for Mitra. Impax Technology will be based in Waterloo.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.